Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2001;32:1481-1486

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimo-Nakanishi, Y.
Right arrow Articles by Mizuno, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimo-Nakanishi, Y.
Right arrow Articles by Mizuno, Y.
Related Collections
Right arrow Arterial thrombosis
Right arrow Thrombosis risk factors
Right arrow Genetics of Stroke
Right arrow Risk Factors for Stroke

(Stroke. 2001;32:1481.)
© 2001 American Heart Association, Inc.


Original Contributions

Polymorphism of the Lipoprotein Lipase Gene and Risk of Atherothrombotic Cerebral Infarction in the Japanese

Yumi Shimo-Nakanishi, MD; Takao Urabe, MD, PhD; Nobutaka Hattori, MD, PhD; Yoshiro Watanabe, MD; Takehiko Nagao, MD; Masayuki Yokochi, MD; Makoto Hamamoto, MD Yoshikuni Mizuno, MD, PhD

From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).

Correspondence to Takao Urabe, MD, Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail t_urabe{at}med.juntendo.ac.jp

Background and Purpose—Lipid and lipoprotein abnormalities have been implicated in the pathogenesis of ischemic cerebrovascular disease and atherosclerosis. Lipoprotein lipase (LPL) plays an important role in plasma lipoprotein metabolism. Several studies have recently reported the presence of a relationship between Ser447Stop mutation of LPL and coronary artery disease. Other polymorphisms (HindIII and PvuII) of the LPL gene have already been shown to correlate significantly with dyslipidemia. We investigated whether these polymorphisms are associated with increased risk of ischemic cerebrovascular disease (CVD).

Methods—We recruited 177 CVD patients (atherothrombotic infarction, n=71; cardioembolic infarction, n=30; lacunar infarction, n=76) and 177 healthy control subjects. Subjects were genotyped for the Ser447Stop mutation and for HindIII/PvuII restriction fragment length polymorphisms of the LPL gene, and the findings were investigated for associations with the clinical subtypes of CVD and with lipid levels.

Results—The Ser447Stop mutation correlated significantly with CVD (0.107 versus 0.158; P=0.035). For the CG+GG versus CC genotype, the odds ratio between control subjects and CVD patients with atherothrombotic infarction was 0.42 (95% CI, 0.18 to 0.99) (P=0.046). Serum HDL cholesterol and triglyceride levels did not correlate significantly with the Ser447Stop genotype. HindIII polymorphism correlated significantly with CVD (0.234 versus 0.169; P=0.031), but the frequency of PvuII polymorphism was not significantly different between groups.

Conclusions—Our results suggest that the Ser447Stop mutation of the LPL gene is a novel genetic marker for low risk of atherothrombotic cerebral infarction.


Key Words: atherosclerosis • cerebral infarction • lipids • polymorphism • risk factors




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Rip, M. C. Nierman, C. J. Ross, J. W. Jukema, M. R. Hayden, J. J.P. Kastelein, E. S.G. Stroes, and J. A. Kuivenhoven
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1236 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. A. Hegele, C. J.D. Ross, J. Twisk, J. A. Kuivenhoven, J. Rip, J. J. Kastelein, and M. R. Hayden
Gene therapy with lipoprotein lipase variant S447X.
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): e25 - e25.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Rip, M. C. Nierman, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, J. N.I. van Miert, B. A. Hutten, J. J.P. Kastelein, J. A. Kuivenhoven, et al.
Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 637 - 642.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. D. Spence, M. R. Ban, and R. A. Hegele
Lipoprotein Lipase (LPL) Gene Variation and Progression of Carotid Artery Plaque
Stroke, May 1, 2003; 34(5): 1176 - 1180.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. F. Meschia
Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research
Stroke, December 1, 2002; 33(12): 2770 - 2774.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. R. Levine and B. M. Coull
Potassium depletion as a risk factor for stroke: Will a banana a day keep your stroke away?
Neurology, August 13, 2002; 59(3): 302 - 303.
[Full Text] [PDF]